PT1676579E - Utilização de tetraciclinas sub-antimicrobianas para o tratamento de rosácea ocular - Google Patents
Utilização de tetraciclinas sub-antimicrobianas para o tratamento de rosácea ocular Download PDFInfo
- Publication number
- PT1676579E PT1676579E PT06004523T PT06004523T PT1676579E PT 1676579 E PT1676579 E PT 1676579E PT 06004523 T PT06004523 T PT 06004523T PT 06004523 T PT06004523 T PT 06004523T PT 1676579 E PT1676579 E PT 1676579E
- Authority
- PT
- Portugal
- Prior art keywords
- tetracycline
- patients
- antimicrobial
- meibom
- tetracyclines
- Prior art date
Links
- 239000004098 Tetracycline Substances 0.000 title claims abstract description 83
- 235000019364 tetracycline Nutrition 0.000 title claims abstract description 81
- 150000003522 tetracyclines Chemical class 0.000 title claims abstract description 80
- 201000004700 rosacea Diseases 0.000 title claims description 33
- 206010072139 Ocular rosacea Diseases 0.000 title claims description 20
- 229940040944 tetracyclines Drugs 0.000 title description 33
- 229960002180 tetracycline Drugs 0.000 claims abstract description 51
- 229930101283 tetracycline Natural products 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 35
- 229960003722 doxycycline Drugs 0.000 claims description 33
- 230000000845 anti-microbial effect Effects 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000004100 Oxytetracycline Substances 0.000 claims description 11
- 229960000625 oxytetracycline Drugs 0.000 claims description 11
- 210000004907 gland Anatomy 0.000 claims description 9
- 235000019366 oxytetracycline Nutrition 0.000 claims description 9
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000011200 topical administration Methods 0.000 claims description 7
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical group C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 230000007794 irritation Effects 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 9
- 230000003111 delayed effect Effects 0.000 abstract description 8
- 230000003628 erosive effect Effects 0.000 abstract description 6
- 230000000306 recurrent effect Effects 0.000 abstract description 6
- 230000000699 topical effect Effects 0.000 abstract description 6
- 210000004175 meibomian gland Anatomy 0.000 abstract 2
- 230000006589 gland dysfunction Effects 0.000 description 28
- 239000002158 endotoxin Substances 0.000 description 23
- 229920006008 lipopolysaccharide Polymers 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 19
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 17
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 description 14
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- IKQRPFTXKQQLJF-IAHYZSEUSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-n-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1 IKQRPFTXKQQLJF-IAHYZSEUSA-N 0.000 description 9
- 108010026132 Gelatinases Proteins 0.000 description 9
- 102000013382 Gelatinases Human genes 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 210000000744 eyelid Anatomy 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 6
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 6
- 241001303601 Rosacea Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical group O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 5
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 5
- -1 Aureocin Chemical compound 0.000 description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 102100030416 Stromelysin-1 Human genes 0.000 description 4
- 101710108790 Stromelysin-1 Proteins 0.000 description 4
- 229940069417 doxy Drugs 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- PZTCVADFMACKLU-UEPZRUIBSA-N (2s)-6-[[[(4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O PZTCVADFMACKLU-UEPZRUIBSA-N 0.000 description 3
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 3
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940063678 vibramycin Drugs 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- RWPPEDAJWOOTPC-DPLGGHQZSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-n-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;nitric acid;trihydrate Chemical compound O.O.O.O[N+]([O-])=O.O[N+]([O-])=O.OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1.OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1 RWPPEDAJWOOTPC-DPLGGHQZSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- OAPVUSSHCBRCOL-KBHRXELFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O OAPVUSSHCBRCOL-KBHRXELFSA-N 0.000 description 1
- IKQRPFTXKQQLJF-VQCPGFMQSA-N (4s,4as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-n-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound OC([C@@]1(O)C(=O)C=2C([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1 IKQRPFTXKQQLJF-VQCPGFMQSA-N 0.000 description 1
- WZNWUDKIQDIRSR-UHFFFAOYSA-N 2-[1,2-dihydroxy-1-(oxiran-2-yl)ethyl]-11-hydroxy-5-methylnaphtho[2,3-h]chromene-4,7,12-trione Chemical compound C=1C(=O)C=2C(C)=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C=2OC=1C(O)(CO)C1CO1 WZNWUDKIQDIRSR-UHFFFAOYSA-N 0.000 description 1
- OWFJMIVZYSDULZ-UHFFFAOYSA-N 2-carbamoyl-4-(dimethylazaniumyl)-5,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracen-1-olate Chemical compound C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(=O)C(C(N)=O)=C(O)C4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011022 Corneal infiltrates Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000004173 Epithelial basement membrane dystrophy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- NPPHVVALVZAFOV-UHFFFAOYSA-N Hydramycin Natural products Cc1cc2C(=O)c3cccc(O)c3C(=O)c2c4OC(=CCc14)C(O)(CO)C5CO5 NPPHVVALVZAFOV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241001117804 Tetrameles Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000791 anti-collagenolytic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940110254 minocin Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940049568 tetralysal Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8487398P | 1998-05-08 | 1998-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1676579E true PT1676579E (pt) | 2009-03-24 |
Family
ID=22187748
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06004523T PT1676579E (pt) | 1998-05-08 | 1999-05-07 | Utilização de tetraciclinas sub-antimicrobianas para o tratamento de rosácea ocular |
| PT99921754T PT1075265E (pt) | 1998-05-08 | 1999-05-07 | Utilizacao de tetraciclinas para o tratamento de doencas da glandula meibomiana |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99921754T PT1075265E (pt) | 1998-05-08 | 1999-05-07 | Utilizacao de tetraciclinas para o tratamento de doencas da glandula meibomiana |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US6455583B1 (enExample) |
| EP (2) | EP1075265B1 (enExample) |
| JP (1) | JP4860038B2 (enExample) |
| AT (2) | ATE418989T1 (enExample) |
| AU (1) | AU763164B2 (enExample) |
| CA (1) | CA2331257C (enExample) |
| DE (2) | DE69940227D1 (enExample) |
| DK (2) | DK1676579T3 (enExample) |
| ES (2) | ES2320579T3 (enExample) |
| PT (2) | PT1676579E (enExample) |
| TW (2) | TWI255714B (enExample) |
| WO (1) | WO1999058131A1 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU763164B2 (en) * | 1998-05-08 | 2003-07-17 | University Of Miami | Use of tetracyclines for treating meibomian gland disease |
| US6432934B1 (en) * | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
| US6506740B1 (en) * | 1998-11-18 | 2003-01-14 | Robert A. Ashley | 4-dedimethylaminotetracycline derivatives |
| EP1171163A1 (en) * | 1999-04-27 | 2002-01-16 | Antibody Systems, Inc. | Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| US7211267B2 (en) * | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| US20040115261A1 (en) * | 2001-04-05 | 2004-06-17 | Ashley Robert A. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
| EP2332547A1 (en) * | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of inflammatory bowel disease |
| US20030073068A1 (en) * | 2001-10-15 | 2003-04-17 | Campbell Robert Edward | Methods for application of tear-based biomarkers to ophthalmic product evaluation and clinical study management |
| US8192749B2 (en) * | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
| WO2003088906A2 (en) * | 2002-04-16 | 2003-10-30 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
| EP1501490A2 (en) * | 2002-05-06 | 2005-02-02 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating mucositis and fungal infection |
| EP1591110B1 (en) * | 2003-01-22 | 2015-03-18 | Senju Pharmaceutical Co., Ltd. | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| WO2004091483A2 (en) * | 2003-04-07 | 2004-10-28 | Shire Laboratories, Inc. | Once daily formulations of tetracyclines |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| WO2005011707A1 (en) * | 2003-07-25 | 2005-02-10 | Warner Chilcott Company, Inc. | A doxycycline metal complex in a solid dosage form |
| WO2007024972A2 (en) * | 2005-08-22 | 2007-03-01 | Quick-Med Technologies, Inc. | Non-leaching absorbent wound dressing |
| CN100340241C (zh) * | 2004-06-28 | 2007-10-03 | 中山大学中山眼科中心 | 一种滴眼液及其制备方法与用途 |
| WO2006078925A2 (en) * | 2005-01-21 | 2006-07-27 | Warner Chilcott Company, Inc. | A tetracycline metal complex in a solid dosage form |
| US7541347B2 (en) | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7544373B2 (en) | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| WO2008024100A2 (en) | 2006-08-21 | 2008-02-28 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction |
| US20070060988A1 (en) * | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US8950405B2 (en) * | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| US7981146B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
| US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
| US8255039B2 (en) | 2006-09-29 | 2012-08-28 | Tearscience, Inc. | Meibomian gland illuminating and imaging |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US20080114423A1 (en) * | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US8128673B2 (en) * | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US8128674B2 (en) * | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US7976573B2 (en) | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US7981147B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| US8007524B2 (en) | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
| US8249695B2 (en) | 2006-09-29 | 2012-08-21 | Tearscience, Inc. | Meibomian gland imaging |
| WO2008089327A1 (en) | 2007-01-17 | 2008-07-24 | Tearscience, Inc. | Methods, systems, and apparatuses for heat treatment for treating meibomian gland dysfunction |
| WO2008097851A1 (en) * | 2007-02-02 | 2008-08-14 | Warner Chilcott Company, Inc. | Tetracycline compositions for topical administration |
| WO2008097850A1 (en) * | 2007-02-02 | 2008-08-14 | Warner Chilcott Company, Inc. | Tretracycline compositions for topical administration |
| US20080312194A1 (en) * | 2007-02-28 | 2008-12-18 | Ousler Iii George W | Methods and compositions for normalizing meibomian gland secretions |
| US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
| AU2008289552B2 (en) * | 2007-08-16 | 2014-10-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| US20090131303A1 (en) * | 2007-11-16 | 2009-05-21 | Bor-Shyue Hong | Methods and compositions for treating dry eye |
| USD613408S1 (en) | 2008-02-06 | 2010-04-06 | Tearscience, Inc. | Eye treatment head gear |
| USD617443S1 (en) | 2008-02-06 | 2010-06-08 | Tearscience, Inc. | Eye treatment goggles |
| USD614303S1 (en) | 2008-02-06 | 2010-04-20 | Tearscience, Inc. | Eye treatment apparatus |
| JP2011515494A (ja) * | 2008-03-26 | 2011-05-19 | エリック ドネンフェルド， | テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法 |
| EP2313103B1 (en) * | 2008-07-10 | 2014-06-18 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
| WO2010017310A1 (en) | 2008-08-06 | 2010-02-11 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| WO2010085572A1 (en) * | 2009-01-23 | 2010-07-29 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with azithromycin |
| EP2413699B1 (en) | 2009-04-01 | 2019-11-20 | Tearscience, Inc. | Ocular surface interferometry (osi) apparatus for imaging an ocular tear film |
| USD638128S1 (en) | 2009-10-06 | 2011-05-17 | Tearscience, Inc. | Ocular device design |
| US8721572B1 (en) | 2010-06-10 | 2014-05-13 | Eyedetec Medical, Inc. | Systems, devices, kits and methods for therapy of the eye |
| US20120190653A1 (en) * | 2011-01-20 | 2012-07-26 | Dow Pharmaceutical Sciences, Inc. | Therapeutic eye drop comprising doxycycline and a stabilizer |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| US9636355B2 (en) | 2011-09-22 | 2017-05-02 | Theo Holdings, Llc | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| WO2013126599A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Meibomian gland dysfunction |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| PT106679B (pt) * | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
| ES2821002T3 (es) | 2013-04-30 | 2021-04-23 | Alcon Inc | Sistemas para el tratamiento de enfermedades del ojo |
| US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
| CN105792729B (zh) | 2013-05-03 | 2018-04-27 | 眼泪科学公司 | 用于对睑板腺进行成像以供睑板腺分析的眼睑照明系统和方法 |
| US10130507B2 (en) | 2013-08-03 | 2018-11-20 | Michael C. Whitehurst | Dry eye treatment device |
| WO2016022066A1 (en) * | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| WO2016079590A1 (en) | 2014-11-19 | 2016-05-26 | Dr. Reddy's Laboratories Ltd. | Modified release doxycycline composition |
| EP3273940B1 (en) | 2015-03-23 | 2020-12-16 | Biopharmx, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| EP3178463A1 (de) | 2015-12-07 | 2017-06-14 | WDT-Wolz-Dental-Technik GmbH | Verfahren zur herstellung eines keramischen körpers, insbesondere eines dentalkeramikrohlings, mit räumlich gezielt einstellbaren ausprägungsgraden physikalischer eigenschaften |
| US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
| US10667951B2 (en) | 2016-08-29 | 2020-06-02 | Nicole Kyongnan Renaud | Eye mask |
| FR3064482B1 (fr) * | 2017-04-03 | 2020-11-13 | Horus Pharma | Composition topique de doxycycline |
| KR20200111177A (ko) | 2017-12-15 | 2020-09-28 | 타르서스 파마수티칼스, 아이엔씨. | 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| JP2025523655A (ja) * | 2022-07-08 | 2025-07-23 | アイシーエム（インスティテュート ドゥ セルヴォ エ デ ラ ムワル エピイエレ） | テトラサイクリン誘導体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788479A (fr) * | 1971-09-06 | 1973-01-02 | Medimpex Gyogyszerkulkereskede | Complexes du tris(hydroxymethyl)aminomethane avec les tetracyclines formant des solutions neutres, stables, tres actives etnon toxiques |
| CA1263606A (en) * | 1985-05-29 | 1989-12-05 | Jeffrey P. Gilbard | Non-toxic opthalmic preparations |
| IE74244B1 (en) * | 1985-10-01 | 1997-07-16 | Bimeda Res Dev Ltd | A process for preparing an antibiotic composition |
| US4866049A (en) * | 1987-08-10 | 1989-09-12 | Spectra Pharmaceutical Services, Inc. | Ophthalmic compositionn and method of using same |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| FR2660193B1 (fr) * | 1990-04-03 | 1994-11-04 | Philippe Maincent | Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules. |
| US5340572A (en) * | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
| US5523297A (en) * | 1993-03-02 | 1996-06-04 | The Research Foundation Of State University Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| AU763164B2 (en) * | 1998-05-08 | 2003-07-17 | University Of Miami | Use of tetracyclines for treating meibomian gland disease |
| US6432934B1 (en) * | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
-
1999
- 1999-05-07 AU AU38879/99A patent/AU763164B2/en not_active Ceased
- 1999-05-07 PT PT06004523T patent/PT1676579E/pt unknown
- 1999-05-07 WO PCT/US1999/009965 patent/WO1999058131A1/en not_active Ceased
- 1999-05-07 EP EP99921754A patent/EP1075265B1/en not_active Expired - Lifetime
- 1999-05-07 DK DK06004523T patent/DK1676579T3/da active
- 1999-05-07 EP EP06004523A patent/EP1676579B1/en not_active Expired - Lifetime
- 1999-05-07 JP JP2000547982A patent/JP4860038B2/ja not_active Expired - Fee Related
- 1999-05-07 AT AT06004523T patent/ATE418989T1/de active
- 1999-05-07 DK DK99921754T patent/DK1075265T3/da active
- 1999-05-07 DE DE69940227T patent/DE69940227D1/de not_active Expired - Lifetime
- 1999-05-07 AT AT99921754T patent/ATE319456T1/de active
- 1999-05-07 DE DE69930252T patent/DE69930252T2/de not_active Expired - Lifetime
- 1999-05-07 US US09/307,182 patent/US6455583B1/en not_active Expired - Fee Related
- 1999-05-07 CA CA2331257A patent/CA2331257C/en not_active Expired - Fee Related
- 1999-05-07 ES ES06004523T patent/ES2320579T3/es not_active Expired - Lifetime
- 1999-05-07 PT PT99921754T patent/PT1075265E/pt unknown
- 1999-05-07 ES ES99921754T patent/ES2260912T3/es not_active Expired - Lifetime
- 1999-05-25 TW TW094111310A patent/TWI255714B/zh not_active IP Right Cessation
- 1999-05-25 TW TW088107469A patent/TWI255713B/zh not_active IP Right Cessation
-
2002
- 2002-08-22 US US10/225,341 patent/US20030114426A1/en not_active Abandoned
-
2005
- 2005-12-07 US US11/297,780 patent/US20060154901A1/en not_active Abandoned
-
2007
- 2007-10-11 US US11/974,435 patent/US20080214510A1/en not_active Abandoned
-
2010
- 2010-07-21 US US12/841,058 patent/US20110039805A1/en not_active Abandoned
-
2011
- 2011-12-01 US US13/309,145 patent/US20120088739A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1075265T3 (da) | 2006-06-26 |
| TW200526232A (en) | 2005-08-16 |
| US20060154901A1 (en) | 2006-07-13 |
| DK1676579T3 (da) | 2009-03-16 |
| US6455583B1 (en) | 2002-09-24 |
| JP4860038B2 (ja) | 2012-01-25 |
| JP2002514602A (ja) | 2002-05-21 |
| US20080214510A1 (en) | 2008-09-04 |
| TWI255713B (en) | 2006-06-01 |
| US20030114426A1 (en) | 2003-06-19 |
| DE69930252T2 (de) | 2006-12-14 |
| EP1676579A3 (en) | 2006-07-12 |
| DE69930252D1 (de) | 2006-05-04 |
| EP1676579A2 (en) | 2006-07-05 |
| EP1676579B1 (en) | 2008-12-31 |
| ES2320579T3 (es) | 2009-05-25 |
| AU3887999A (en) | 1999-11-29 |
| AU763164B2 (en) | 2003-07-17 |
| US20110039805A1 (en) | 2011-02-17 |
| WO1999058131A1 (en) | 1999-11-18 |
| EP1075265A1 (en) | 2001-02-14 |
| ATE418989T1 (de) | 2009-01-15 |
| CA2331257C (en) | 2012-01-03 |
| HK1034899A1 (en) | 2001-11-09 |
| ES2260912T3 (es) | 2006-11-01 |
| CA2331257A1 (en) | 1999-11-18 |
| ATE319456T1 (de) | 2006-03-15 |
| DE69940227D1 (de) | 2009-02-12 |
| EP1075265B1 (en) | 2006-03-08 |
| HK1089696A1 (en) | 2006-12-08 |
| TWI255714B (en) | 2006-06-01 |
| PT1075265E (pt) | 2006-07-31 |
| US20120088739A1 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1676579E (pt) | Utilização de tetraciclinas sub-antimicrobianas para o tratamento de rosácea ocular | |
| US10213392B2 (en) | Pharmaceutical composition for use in medical and veterinary ophthalmology | |
| EP1541151B1 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | |
| US5891913A (en) | Ophthalmic and aural compositions containing diclofenac potassium | |
| US20020013345A1 (en) | Treatment of diseases of the eye characterized by the formation of metalloproteinase | |
| JPH01104023A (ja) | 眼用保存製剤およびその製法 | |
| EP0093380A2 (en) | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma | |
| Katz et al. | Bacitracin: a unique topical antibiotic sensitizer | |
| JPS6366122A (ja) | 緑内障の局所治療用組成物 | |
| EP0979652B1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
| Pflugfelder et al. | Method for treating meibomian gland disease | |
| HK1089696B (en) | Use of sub-antimicrobial tetracyclines for treating ocular rosacea | |
| HK1034899B (en) | Use of tetracyclines for treating meibomian gland disease | |
| KR20050013238A (ko) | 각결막 상피세포 장해치료약 또는 예방약 | |
| EP4591860A1 (en) | Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome | |
| Singh et al. | 5-Day Oral Azithromycin Versus1-Monthcontinuous Topical Azithromycin Ointment in Meibomian Gland Dysfunction: A Randomised Double-Masked Open-Label Clinical Trial |